Increased intraocular pressure (IOP), also known as ocular hypertension, is widely associated with open-angle and narrow-angle glaucoma. These servere eye diseases may lead to blindness. Current therapeutic approaches use carbonic anhydrase inhibitors (CA Inhibitors), beta blockers, alpha2-receptor agonists, prostaglandins and cholinergics. It was recently found that histamine H3-receptor (H3R) antagonists  also exhibit a specific mode of action for the efficient reduction of IOP. However, all treatments have the common disadvantage that only one active compound has to be selected. In addition, the IOP is caused by various factors that should ideally be addressed simultaneously.

The invention addresses these disadvantages. Novel compounds based on a combination of classical pharmacophore modes of action are provided whereby the compounds exhibit inhibitory effects atf H3R  and at CA both in the nanomolar concentration range. This combination as a newly-synthezised single compound with two simultaneous modes of action has the advantages of uniform pharmacokinetics and improves the ways of application due to their physicochemical properties. Through the simultaneous attack of two target structures, broader applications, longer duration and thereby improved effects can be realized as new therapeutic principle.